Synthesis and Structure–Activity Relationship Correlations of Gnidimacrin Derivatives as Potent HIV‑1 Inhibitors and HIV Latency Reversing Agents

Currently, due to the HIV latency mechanism, the search continues for effective drugs to combat this issue and provide a cure for AIDS. Gnidimacrin activates latent HIV-1 replication and inhibits HIV-1 infection at picomolar concentrations. This natural diterpene was able to markedly reduce the late...

Full description

Saved in:
Bibliographic Details
Published inJournal of medicinal chemistry Vol. 62; no. 15; pp. 6958 - 6971
Main Authors Liu, Qingbo, Cheng, Yung-Yi, Li, Wei, Huang, Li, Asada, Yoshihisa, Hsieh, Min-Tsang, Morris-Natschke, Susan L, Chen, Chin-Ho, Koike, Kazuo, Lee, Kuo-Hsiung
Format Journal Article
LanguageEnglish
Published WASHINGTON American Chemical Society 08.08.2019
Amer Chemical Soc
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Currently, due to the HIV latency mechanism, the search continues for effective drugs to combat this issue and provide a cure for AIDS. Gnidimacrin activates latent HIV-1 replication and inhibits HIV-1 infection at picomolar concentrations. This natural diterpene was able to markedly reduce the latent HIV-1 DNA level and the frequency of latently infected cells. Therefore, gnidimacrin is an excellent lead compound, and its anti-HIV potential merits further investigation. Twenty-nine modified gnidimacrin derivatives were synthesized and evaluated in assays for HIV replication and latency activation to establish which molecular structures must be maintained and which can tolerate changes that may be needed for better pharmacological properties. The results indicated that hydroxyl substituents at C-5 and C-20 are essential, while derivatives modified at 3-OH with aromatic esters retain anti-HIV replication and latent activation activities. The half-lives of the potent GM derivatives are over 20 h, which implies that they are stable in the plasm even though they contain ester linkages. The established structure–activity relationship should be useful in the development of gnidimacrin or structurally related compounds as clinical trial candidates.
AbstractList Currently, due to the HIV latency mechanism, the search continues for effective drugs to combat this issue and provide a cure for AIDS. Gnidimacrin activates latent HIV-1 replication and inhibits HIV-1 infection at picomolar concentrations. This natural diterpene was able to markedly reduce the latent HIV-1 DNA level and the frequency of latently infected cells. Therefore, gnidimacrin is an excellent lead compound, and its anti-HIV potential merits further investigation. Twenty-nine modified gnidimacrin derivatives were synthesized and evaluated in assays for HIV replication and latency activation to establish which molecular structures must be maintained and which can tolerate changes that may be needed for better pharmacological properties. The results indicated that hydroxyl substituents at C-5 and C-20 are essential, while derivatives modified at 3-OH with aromatic esters retain anti-HIV replication and latent activation activities. The half-lives of the potent GM derivatives are over 20 h, which implies that they are stable in the plasm even though they contain ester linkages. The established structure-activity relationship should be useful in the development of gnidimacrin or structurally related compounds as clinical trial candidates.
Currently, due to the HIV latency mechanism, the search continues for effective drugs to combat this issue and provide a cure for AIDS. Gnidimacrin activates latent HIV-1 replication and inhibits HIV-1 infection at picomolar concentrations. This natural diterpene was able to markedly reduce the latent HIV-1 DNA level and the frequency of latently infected cells. Therefore, gnidimacrin is an excellent lead compound, and its anti-HIV potential merits further investigation. Twenty-nine modified gnidimacrin derivatives were synthesized and evaluated in assays for HIV replication and latency activation to establish which molecular structures must be maintained and which can tolerate changes that may be needed for better pharmacological properties. The results indicated that hydroxyl substituents at C-5 and C-20 are essential, while derivatives modified at 3-OH with aromatic esters retain anti-HIV replication and latent activation activities. The half-lives of the potent GM derivatives are over 20 h, which implies that they are stable in the plasm even though they contain ester linkages. The established structure-activity relationship should be useful in the development of gnidimacrin or structurally related compounds as clinical trial candidates.Currently, due to the HIV latency mechanism, the search continues for effective drugs to combat this issue and provide a cure for AIDS. Gnidimacrin activates latent HIV-1 replication and inhibits HIV-1 infection at picomolar concentrations. This natural diterpene was able to markedly reduce the latent HIV-1 DNA level and the frequency of latently infected cells. Therefore, gnidimacrin is an excellent lead compound, and its anti-HIV potential merits further investigation. Twenty-nine modified gnidimacrin derivatives were synthesized and evaluated in assays for HIV replication and latency activation to establish which molecular structures must be maintained and which can tolerate changes that may be needed for better pharmacological properties. The results indicated that hydroxyl substituents at C-5 and C-20 are essential, while derivatives modified at 3-OH with aromatic esters retain anti-HIV replication and latent activation activities. The half-lives of the potent GM derivatives are over 20 h, which implies that they are stable in the plasm even though they contain ester linkages. The established structure-activity relationship should be useful in the development of gnidimacrin or structurally related compounds as clinical trial candidates.
Author Liu, Qingbo
Morris-Natschke, Susan L
Chen, Chin-Ho
Huang, Li
Asada, Yoshihisa
Lee, Kuo-Hsiung
Li, Wei
Koike, Kazuo
Hsieh, Min-Tsang
Cheng, Yung-Yi
AuthorAffiliation Faculty of Pharmaceutical Sciences
University of North Carolina
Toho University
Natural Products Research Laboratories, UNC Eshelman School of Pharmacy
Surgical Science, Department of Surgery
Chinese Medicine Research and Development Center
Key Laboratory of Structure-Based Drug Design and Discovery of Ministry of Education
China Medical University and Hospital
AuthorAffiliation_xml – name: University of North Carolina
– name: Surgical Science, Department of Surgery
– name: Chinese Medicine Research and Development Center
– name: Natural Products Research Laboratories, UNC Eshelman School of Pharmacy
– name: China Medical University and Hospital
– name: Faculty of Pharmaceutical Sciences
– name: Toho University
– name: Key Laboratory of Structure-Based Drug Design and Discovery of Ministry of Education
– name: Key Laboratory of Structure-Based Drug Design and Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China
– name: Natural Products Research Laboratories, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, United States
– name: Chinese Medicine Research and Development Center, China Medical University and Hospital, Taichung 40402, Taiwan
– name: Surgical Science, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, United States
– name: Faculty of Pharmaceutical Sciences, Toho University, Miyama 2-2-1, Funabashi 274-8510, Chiba, Japan
Author_xml – sequence: 1
  givenname: Qingbo
  surname: Liu
  fullname: Liu, Qingbo
  organization: Key Laboratory of Structure-Based Drug Design and Discovery of Ministry of Education
– sequence: 2
  givenname: Yung-Yi
  surname: Cheng
  fullname: Cheng, Yung-Yi
  organization: China Medical University and Hospital
– sequence: 3
  givenname: Wei
  orcidid: 0000-0003-4143-8597
  surname: Li
  fullname: Li, Wei
  email: liwei@phar.toho-u.ac.jp
  organization: Toho University
– sequence: 4
  givenname: Li
  surname: Huang
  fullname: Huang, Li
  organization: Surgical Science, Department of Surgery
– sequence: 5
  givenname: Yoshihisa
  surname: Asada
  fullname: Asada, Yoshihisa
  organization: Toho University
– sequence: 6
  givenname: Min-Tsang
  surname: Hsieh
  fullname: Hsieh, Min-Tsang
  organization: China Medical University and Hospital
– sequence: 7
  givenname: Susan L
  surname: Morris-Natschke
  fullname: Morris-Natschke, Susan L
  organization: University of North Carolina
– sequence: 8
  givenname: Chin-Ho
  orcidid: 0000-0001-6880-2104
  surname: Chen
  fullname: Chen, Chin-Ho
  email: chc@duke.edu
  organization: Surgical Science, Department of Surgery
– sequence: 9
  givenname: Kazuo
  surname: Koike
  fullname: Koike, Kazuo
  email: koike@phar.toho-u.ac.jp
  organization: Toho University
– sequence: 10
  givenname: Kuo-Hsiung
  orcidid: 0000-0002-6562-0070
  surname: Lee
  fullname: Lee, Kuo-Hsiung
  email: khlee@unc.edu
  organization: China Medical University and Hospital
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31343875$$D View this record in MEDLINE/PubMed
BookMark eNqNUs1uEzEQtlARTQtvgJCPSCjBP-vdLAekaKFtpEggClwtr9ebuNrYqe0Nyq2vUCFesE_CpEkq4ACcbM98P_J8c4KOnHcGoeeUjChh9LXScXS1NI1emOWorAnhvHyEBlQwMszGJDtCA0IYG7Kc8WN0EuMVAQxl_Ak65pRnfFyIAfpxuXFpYaKNWLkGX6bQ69QHc3fzfaKTXdu0wZ9Mp5L1Li7sClc-hMMb-xafO9vYpdLBOvzOBLuG1tqAWsQffTIu4Yvp17ubW4qnbmFrm3zYWUEZzxQg9NZhbUK0bo4nc6DEp-hxq7ponu3PU_Tl7P3n6mI4-3A-rSazoRJUpCGvi0JRogpj6rIlUFNsTEwtmkw0uaaKGa7zQpSCC1qSmue6FSUnutZZw2Bgp-jtTnfV19tRgndQnVwF-FHYSK-s_L3j7ELO_VoWWcYYzUHg5V4g-OvexCSXNmrTdcoZ30fJWC6KoiR8C33xq9eDySELALzaAb6Z2rdRWxiNeYBBeJCqICSHGykBPf5_dGXTfWKV710C6psdVQcfYzCt1Ps-_NF2khK53TAJGyYPGyb3Gwbk7A_ywfMfNLKj3Xd9Hxzk-nfKTwBx7MA
CitedBy_id crossref_primary_10_1016_j_ejmech_2023_115449
crossref_primary_10_1021_acsinfecdis_4c00194
crossref_primary_10_57634_RCR5056
crossref_primary_10_1021_acs_jnatprod_2c00894
crossref_primary_10_1142_S0192415X22500483
crossref_primary_10_1007_s11904_024_00712_1
crossref_primary_10_1021_acs_jnatprod_0c01039
crossref_primary_10_1016_j_phytochem_2020_112360
crossref_primary_10_1021_acs_jmedchem_1c01973
crossref_primary_10_1007_s11172_024_4312_9
crossref_primary_10_1097_HM9_0000000000000004
crossref_primary_10_1021_acs_orglett_9b03539
crossref_primary_10_1016_j_fitote_2023_105731
crossref_primary_10_1007_s11418_021_01551_9
crossref_primary_10_3390_molecules27238280
crossref_primary_10_1002_med_21638
crossref_primary_10_1016_j_fitote_2020_104810
crossref_primary_10_1007_s11418_023_01713_x
crossref_primary_10_1021_acs_jnatprod_2c00618
Cites_doi 10.1128/AAC.01361-18
10.1073/pnas.96.26.15109
10.1016/j.fitote.2014.02.018
10.1016/0092-8674(95)90011-X
10.1021/acs.jmedchem.6b00461
10.1021/np50104a008
10.1016/j.ejmech.2018.07.020
10.1021/cr300481j
10.1016/j.immuni.2012.01.014
10.1021/acs.jmedchem.5b01233
10.1021/acsmedchemlett.8b00012
10.1016/j.antiviral.2018.07.016
10.1371/journal.pone.0026677
10.1021/np900821e
10.1021/jm301040s
10.1002/0471141755.ph0706s19
10.1038/387183a0
10.1038/487439a
10.1021/ol200889s
10.1016/j.antiviral.2018.02.017
10.1016/j.bmc.2012.05.043
ContentType Journal Article
DBID AAYXX
CITATION
17B
1KM
AAWJD
BLEPL
DTL
EGQ
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.1021/acs.jmedchem.9b00339
DatabaseName CrossRef
Web of Knowledge
Index Chemicus
Web of Science - Science Citation Index Expanded - 2019
Web of Science Core Collection
Science Citation Index Expanded
Web of Science Primary (SCIE, SSCI & AHCI)
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
Web of Science
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic

Web of Science

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 1KM
  name: Index Chemicus
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/woscc/search-with-editions?editions=WOS.IC
  sourceTypes:
    Enrichment Source
    Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Chemistry
Pharmacy, Therapeutics, & Pharmacology
EISSN 1520-4804
EndPage 6971
ExternalDocumentID PMC7442216
31343875
000480500600009
10_1021_acs_jmedchem_9b00339
d058800779
Genre Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: U.S.-Japan Cooperative Medical Sciences Program Collaborative Award from AMED
– fundername: U.S.-Japan Cooperative Medical Sciences Program Collaborative Award from NIAID
– fundername: NIH from the National Institute of Allergy and Infectious Diseases; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)
  grantid: AI33066
– fundername: Japan Society for Promotion of Science KAKENHI; Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT); Japan Society for the Promotion of Science; Grants-in-Aid for Scientific Research (KAKENHI)
  grantid: K08348; 26460133
– fundername: NIAID NIH HHS
  grantid: R01 AI033066
– fundername: NIAID NIH HHS
  grantid: P30 AI064518
GroupedDBID -
.K2
55A
5GY
5RE
5VS
7~N
AABXI
ABFLS
ABMVS
ABOCM
ABPTK
ABUCX
ACGFS
ACJ
ACS
AEESW
AENEX
AFEFF
ALMA_UNASSIGNED_HOLDINGS
AQSVZ
BAANH
CS3
DU5
EBS
ED
ED~
EJD
F5P
GNL
IH9
IHE
JG
JG~
K2
L7B
LG6
P2P
ROL
TN5
UI2
VF5
VG9
W1F
WH7
X
XFK
YZZ
ZY4
---
-~X
4.4
6P2
AAHBH
AAYXX
ABBLG
ABJNI
ABLBI
ABQRX
ACGFO
ADHLV
AGXLV
AHGAQ
CITATION
CUPRZ
GGK
IH2
XSW
YQT
17B
1KM
BLEPL
DTL
GROUPED_WOS_SCIENCE_CITATION_INDEX_EXPANDED
GROUPED_WOS_WEB_OF_SCIENCE
ABTAH
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ID FETCH-LOGICAL-a515t-3b77a10a7eeb9f0515a280eb5d45d6c1a2e3c6759535190b36cf5930cbc4d2033
IEDL.DBID ACS
ISICitedReferencesCount 19
ISICitedReferencesURI https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestApp=WOS&DestLinkType=CitingArticles&UT=000480500600009
ISSN 0022-2623
1520-4804
IngestDate Thu Aug 21 14:18:13 EDT 2025
Thu Jul 10 19:16:42 EDT 2025
Thu Apr 03 07:02:27 EDT 2025
Wed Jul 09 08:28:07 EDT 2025
Fri Aug 29 16:17:26 EDT 2025
Thu Apr 24 22:54:50 EDT 2025
Tue Jul 01 00:43:01 EDT 2025
Thu Aug 27 13:43:25 EDT 2020
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 15
Keywords ANTI-AIDS AGENTS
ELIMINATION
REPLICATION
DITERPENOIDS
Language English
License https://doi.org/10.15223/policy-029
https://doi.org/10.15223/policy-037
https://doi.org/10.15223/policy-045
LinkModel DirectLink
LogoURL https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg
MergedId FETCHMERGED-LOGICAL-a515t-3b77a10a7eeb9f0515a280eb5d45d6c1a2e3c6759535190b36cf5930cbc4d2033
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Q.L. and Y.-Y.C. contributed equally.
ORCID 0000-0002-6562-0070
0000-0003-4143-8597
0000-0001-6880-2104
0000-0001-7473-2835
0000-0002-4360-8513
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/7442216
PMID 31343875
PQID 2265779036
PQPubID 23479
PageCount 14
ParticipantIDs webofscience_primary_000480500600009CitationCount
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7442216
webofscience_primary_000480500600009
proquest_miscellaneous_2265779036
pubmed_primary_31343875
crossref_citationtrail_10_1021_acs_jmedchem_9b00339
crossref_primary_10_1021_acs_jmedchem_9b00339
acs_journals_10_1021_acs_jmedchem_9b00339
ProviderPackageCode JG~
55A
AABXI
GNL
VF5
7~N
ACJ
VG9
W1F
ACS
AEESW
AFEFF
.K2
ABMVS
ABUCX
IH9
BAANH
AQSVZ
ED~
UI2
CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2019-08-08
PublicationDateYYYYMMDD 2019-08-08
PublicationDate_xml – month: 08
  year: 2019
  text: 2019-08-08
  day: 08
PublicationDecade 2010
PublicationPlace WASHINGTON
PublicationPlace_xml – name: WASHINGTON
– name: United States
PublicationTitle Journal of medicinal chemistry
PublicationTitleAbbrev J MED CHEM
PublicationTitleAlternate J. Med. Chem
PublicationYear 2019
Publisher American Chemical Society
Amer Chemical Soc
Publisher_xml – name: American Chemical Society
– name: Amer Chemical Soc
References ref9/cit9
ref17/cit17
ref6/cit6
ref10/cit10
ref3/cit3
ref18/cit18
ref19/cit19
ref21/cit21
ref11/cit11
ref12/cit12
ref15/cit15
ref16/cit16
ref13/cit13
ref14/cit14
ref8/cit8
ref5/cit5
ref2/cit2
ref4/cit4
ref1/cit1
ref20/cit20
ref7/cit7
Huang, SZ (WOS:000336819400005) 2014; 95
Deeks, SG (WOS:000306815300026) 2012; 487
Zhao, Y (WOS:000385607100038) 2016; 59
Spivak, AM (WOS:000448186900058) 2018; 62
Johnson, TA (WOS:000305952500019) 2012; 20
ZHANG, GG (WOS:A1995RD76800012) 1995; 81
Chun, TW (WOS:A1997WX94500055) 1997; 387
Qian, K (WOS:000309153500016) 2012; 55
Huang, L (WOS:000296515200040) 2011; 6
Tietjen, I (WOS:000429397800012) 2018; 152
Davey, RT (WOS:000084375400079) 1999; 96
Hartman, D. A (000480500600009.8) 2003; 19
FUJIOKA, T (WOS:A1994NA31400008) 1994; 57
Asada, Y (WOS:000291128500028) 2011; 13
Liu, QB (WOS:000443663200044) 2018; 156
Lai, WH (WOS:000364796100022) 2015; 58
Shan, L (WOS:000302048400019) 2012; 36
Das, J (WOS:000347139900005) 2014; 114
Andersen, RJ (WOS:000446144000008) 2018; 158
Huang, L (WOS:000427331200018) 2018; 9
Lee, KH (WOS:000275885000039) 2010; 73
References_xml – ident: ref17/cit17
  doi: 10.1128/AAC.01361-18
– ident: ref11/cit11
  doi: 10.1073/pnas.96.26.15109
– ident: ref15/cit15
  doi: 10.1016/j.fitote.2014.02.018
– ident: ref19/cit19
  doi: 10.1016/0092-8674(95)90011-X
– ident: ref5/cit5
  doi: 10.1021/acs.jmedchem.6b00461
– ident: ref2/cit2
  doi: 10.1021/np50104a008
– ident: ref16/cit16
  doi: 10.1016/j.ejmech.2018.07.020
– ident: ref18/cit18
  doi: 10.1021/cr300481j
– ident: ref13/cit13
  doi: 10.1016/j.immuni.2012.01.014
– ident: ref1/cit1
  doi: 10.1021/acs.jmedchem.5b01233
– ident: ref8/cit8
  doi: 10.1021/acsmedchemlett.8b00012
– ident: ref9/cit9
  doi: 10.1016/j.antiviral.2018.07.016
– ident: ref14/cit14
  doi: 10.1371/journal.pone.0026677
– ident: ref3/cit3
  doi: 10.1021/np900821e
– ident: ref4/cit4
  doi: 10.1021/jm301040s
– ident: ref20/cit20
  doi: 10.1002/0471141755.ph0706s19
– ident: ref10/cit10
  doi: 10.1038/387183a0
– ident: ref12/cit12
  doi: 10.1038/487439a
– ident: ref21/cit21
  doi: 10.1021/ol200889s
– ident: ref6/cit6
  doi: 10.1016/j.antiviral.2018.02.017
– ident: ref7/cit7
  doi: 10.1016/j.bmc.2012.05.043
– volume: 36
  start-page: 491
  year: 2012
  ident: WOS:000302048400019
  article-title: Stimulation of HIV-1-Specific Cytolytic T Lymphocytes Facilitates Elimination of Latent Viral Reservoir after Virus Reactivation
  publication-title: IMMUNITY
  doi: 10.1016/j.immuni.2012.01.014
– volume: 387
  start-page: 183
  year: 1997
  ident: WOS:A1997WX94500055
  article-title: Quantification of latent tissue reservoirs and total body viral load in HIV-1 Infection
  publication-title: NATURE
– volume: 95
  start-page: 34
  year: 2014
  ident: WOS:000336819400005
  article-title: Anti-HIV-1 tigliane diterpenoids from Excoecaria acertiflia Didr
  publication-title: FITOTERAPIA
  doi: 10.1016/j.fitote.2014.02.018
– volume: 57
  start-page: 243
  year: 1994
  ident: WOS:A1994NA31400008
  article-title: ANTI-AIDS AGENTS .11. BETULINIC ACID AND PLATANIC ACID AS ANTI-HIV PRINCIPLES FROM SYZIGIUM-CLAVIFLORUM, AND THE ANTI-HIV ACTIVITY OF STRUCTURALLY RELATED TRITERPENOIDS
  publication-title: JOURNAL OF NATURAL PRODUCTS
– volume: 20
  start-page: 4348
  year: 2012
  ident: WOS:000305952500019
  article-title: Myxobacteria versus sponge-derived alkaloids: The bengamide family identified as potent immune modulating agents by scrutiny of LC-MS/ELSD libraries
  publication-title: BIOORGANIC & MEDICINAL CHEMISTRY
  doi: 10.1016/j.bmc.2012.05.043
– volume: 96
  start-page: 15109
  year: 1999
  ident: WOS:000084375400079
  article-title: HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression
  publication-title: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
– volume: 13
  start-page: 2904
  year: 2011
  ident: WOS:000291128500028
  article-title: Stelleralides A-C, Novel Potent Anti-HIV Daphnane-Type Diterpenoids from Stellera chamaejasme L.
  publication-title: ORGANIC LETTERS
  doi: 10.1021/ol200889s
– volume: 59
  start-page: 9262
  year: 2016
  ident: WOS:000385607100038
  article-title: Incorporation of Privileged Structures into Bevirimat Can Improve Activity against Wild-Type and Bevirimat-Resistant HIV-1
  publication-title: JOURNAL OF MEDICINAL CHEMISTRY
  doi: 10.1021/acs.jmedchem.6b00461
– volume: 158
  start-page: 63
  year: 2018
  ident: WOS:000446144000008
  article-title: Natural product-derived compounds in HIV suppression, remission, and eradication strategies
  publication-title: ANTIVIRAL RESEARCH
  doi: 10.1016/j.antiviral.2018.07.016
– volume: 55
  start-page: 8128
  year: 2012
  ident: WOS:000309153500016
  article-title: Anti-AIDS Agents 90. Novel C-28 Modified Bevirimat Analogues as Potent HIV Maturation Inhibitors
  publication-title: JOURNAL OF MEDICINAL CHEMISTRY
  doi: 10.1021/jm301040s
– volume: 487
  start-page: 439
  year: 2012
  ident: WOS:000306815300026
  article-title: HIV Shock and kill
  publication-title: NATURE
– volume: 58
  start-page: 8638
  year: 2015
  ident: WOS:000364796100022
  article-title: Gnidimacrin, a Potent Anti-HIV Diterpene, Can Eliminate Latent HIV-1 Ex Vivo by Activation of Protein Kinase C beta
  publication-title: JOURNAL OF MEDICINAL CHEMISTRY
  doi: 10.1021/acs.jmedchem.5b01233
– volume: 152
  start-page: 94
  year: 2018
  ident: WOS:000429397800012
  article-title: Inhibition of NF-kappa B-dependent HIV-1 replication by the marine natural product bengamide A
  publication-title: ANTIVIRAL RESEARCH
  doi: 10.1016/j.antiviral.2018.02.017
– volume: 114
  start-page: 12108
  year: 2014
  ident: WOS:000347139900005
  article-title: C1 Domains: Structure and Ligand-Binding Properties
  publication-title: CHEMICAL REVIEWS
  doi: 10.1021/cr300481j
– volume: 19
  start-page: 7
  year: 2003
  ident: 000480500600009.8
  article-title: Determination of the stability of drugs in plasma
  publication-title: Curr. Protoc. Pharmacol
– volume: 62
  start-page: ARTN e01361-18
  year: 2018
  ident: WOS:000448186900058
  article-title: Synthetic Ingenols Maximize Protein Kinase C-Induced HIV-1 Latency Reversal
  publication-title: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
  doi: 10.1128/AAC.01361-18
– volume: 9
  start-page: 268
  year: 2018
  ident: WOS:000427331200018
  article-title: Elimination of HIV-1 Latently Infected Cells by Gnidimacrin and a Selective HDAC Inhibitor
  publication-title: ACS MEDICINAL CHEMISTRY LETTERS
  doi: 10.1021/acsmedchemlett.8b00012
– volume: 156
  start-page: 618
  year: 2018
  ident: WOS:000443663200044
  article-title: Identification, structural modification, and dichotomous effects on human immunodeficiency virus type 1 (HIV-1) replication of ingenane esters from Euphorbia kansui
  publication-title: EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
  doi: 10.1016/j.ejmech.2018.07.020
– volume: 6
  start-page: ARTN e26677
  year: 2011
  ident: WOS:000296515200040
  article-title: Picomolar Dichotomous Activity of Gnidimacrin Against HIV-1
  publication-title: PLOS ONE
  doi: 10.1371/journal.pone.0026677
– volume: 81
  start-page: 917
  year: 1995
  ident: WOS:A1995RD76800012
  article-title: CRYSTAL-STRUCTURE OF THE CYS2 ACTIVATOR-BINDING DOMAIN OF PROTEIN-KINASE C-DELTA IN COMPLEX WITH PHORBOL ESTER
  publication-title: CELL
– volume: 73
  start-page: 500
  year: 2010
  ident: WOS:000275885000039
  article-title: Discovery and Development of Natural Product-Derived Chemotherapeutic Agents Based on a Medicinal Chemistry Approach
  publication-title: JOURNAL OF NATURAL PRODUCTS
  doi: 10.1021/np900821e
SSID ssj0003123
Score 2.401097
Snippet Currently, due to the HIV latency mechanism, the search continues for effective drugs to combat this issue and provide a cure for AIDS. Gnidimacrin activates...
Source Web of Science
SourceID pubmedcentral
proquest
pubmed
webofscience
crossref
acs
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 6958
SubjectTerms Animals
Anti-HIV Agents - chemical synthesis
Anti-HIV Agents - pharmacology
Chemistry, Medicinal
Diterpenes - chemical synthesis
Diterpenes - pharmacology
HIV-1 - drug effects
HIV-1 - physiology
Humans
Life Sciences & Biomedicine
Pharmacology & Pharmacy
Plant Extracts - chemical synthesis
Plant Extracts - isolation & purification
Plant Extracts - pharmacology
Plant Roots
Rats
Rats, Sprague-Dawley
Reactive Oxygen Species - chemical synthesis
Reactive Oxygen Species - pharmacology
Science & Technology
Structure-Activity Relationship
Virus Latency - drug effects
Virus Latency - physiology
Title Synthesis and Structure–Activity Relationship Correlations of Gnidimacrin Derivatives as Potent HIV‑1 Inhibitors and HIV Latency Reversing Agents
URI http://dx.doi.org/10.1021/acs.jmedchem.9b00339
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestApp=WOS&DestLinkType=FullRecord&UT=000480500600009
https://www.ncbi.nlm.nih.gov/pubmed/31343875
https://www.proquest.com/docview/2265779036
https://pubmed.ncbi.nlm.nih.gov/PMC7442216
Volume 62
WOS 000480500600009
WOSCitedRecordID wos000480500600009
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELagHOBSoLzCS0aqKiE12ziO8ziuAmWLEKy0Leotsh2HDQVv1WSRllP_AkL8wf4Sxs5j2RbUcowzHiv2OPONPP4Goc2IBAKAhXIZyQMIULzETTwu3SgueJFDoxKW7fN9ODoI3h6yw2WgeP4E3yc7XFaDzyZZcaq-DgyDH6XJdXTDD-PIBFvDdNL_eSnxaccO7oNf767K_UOLcUiyWnVIF1Dm35Mlzzko64x2b6MP3ZWeJgflaDCvxUB-v8jweMXvvIPWW1yKh40h3UXXlN5AN9OuHNwG2ho3JNeLbby_vLNVbeMtPF7SXy_uoV-ThQZUWZUV5jrHE0tQOz9RZ6c_h7KpVYH7FLxpeYxTUyCkfcazAr_RZV6CvpNS41ewQb5ZbnLQVuHxDCB-jUd7H89OfxC8p6elKE29IDsUNON33AQBZgSbb6I_4aG5PFbdRwe7r_fTkdsWf3A5QKzapSKKOPF4pJRIClOJhvuxpwTLA5aHknBfUQnRTsJMiUFP0FAWLKGeFDLIfZi8B2hNz7R6hHDOw5DnMfU8TgMZMMGYgLiQiwLiYZB10EuY_KzdvFVmz-V9ktnGdkWydkUcRDtryWTLom6KeXy5pJfb9zpuWEQukX_RGWIGy2zOcLhWs3mVAVpmhiKShg562Bhmr5ESGlCIPx0UrZhsL2CoxFff6HJqKcWjIPB9Ajo3_zTuvmNDPcAMeY8B5Q4iVxFL2_kx7Ar14_-Y5CfoFuDSxOZZxk_RGhiqegbYrxbP7Yb_DUweW0U
linkProvider American Chemical Society
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwzV1bb9MwFLam8TBeuIxbuRppTEJaSmzn0jzwUHWMlo2pUju0t8x2HBou7rS0oPK0v4AQP4G_wg_ZL-HYuZQO0OBhEo9x7JPo-FyT4-8gtBYST0BgoRyfJB4kKG7kRC6XTthKeZrAoBIW7XM36O55L_b9_SX0rToLAy-RA6Xc_sSfowuQJ2bsjalZHKn3TQPkx1hU1lJuq9lHyNTyp71N2NZHlG49G3a6TtlMwOHgsicOE2HIictDpUSUms4mnLZcJfzE85NAEk4VkxA9R75pWecKFsjUj5grhfQS6prvnmDpL0D8Q02O1-4MaoPPCGUVKDmFcKI6ofeHtzZ-UOaLfvCX4Pb3NZqn_KL1gVuX0feae7b05W1zOhFN-ekUsOR_z94r6FIZheN2oTZX0ZLSq2ilUzW_W0Xr_QLSe7aBh_MTavkGXsf9Odj37Br6OphpiKHzLMdcJ3hg4XinR-rk-EtbFp05cF1wOMoOcce0Qymv8TjFz3WWZEDvKNN4E8zBB4vEDtRy3B9DQjPB3d6rk-PPBPf0KBOZ6Y5kHwXDeIeblMc8wVbX6Ne4bY7K5dfR3rmw7wZa1mOtbiGc8CDgSYu5Lmee9Hzh-wKyYC5SyP5hbgM9hs2OS1OVx7YKgZLYDpYSEJcS0ECsEtJYlpjxpnXJuzNWOfWqwwIz5Yz5Dyv5j2GbzR8rrtV4mseQG_gGEJMFDXSz0IeaIiPMY5BtN1C4oCn1BAOcvnhHZyMLoB56HqUEaK79rFP1wgJowTdQRSYFaSDyN9M6JX8MlsTk9j8w-QFa6Q5f7sQ7vd3tO-giROSRrTBt3UXLILTqHkS9E3Hf2hyMDs5bC38A3NG8rA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLamIQEvXMatXI00JiEtJY7jpHngoWopLZumSt3Q3oLtODRc0mpuQeVpfwEhfgR_hZ-xX8KxcxkdoMHDHniMY59Yxz63-Pg7CK2HxBfgWCiHkcSHAMWNnMjl0glbKU8TaFTCon3uBP09_8U-219B36q7MDAJDZS0PcQ3Uj1N0hJhgDwx7W9M3uJYvW8aMD9KozKfckstPkK0pp8OurC0jzyv92y303fKggIOB7M9c6gIQ05cHiolotRUN-Fey1WCJT5LAkm4p6gEDzpipmydK2ggUxZRVwrpJ55r_n2Ctj9nTgpNnNfujGqlT4lHK2ByD1yK6pbeH2ZtbKHUy7bwFwf393maJ2yjtYO9y-h7zUGb_vK2OZ-Jpvx0Alzyv2DxFXSp9MZxuxCfq2hF5WvoQqcqgreGNoYFtPdiE-8e31TTm3gDD49BvxfX0NfRIgdfWmca8zzBIwvLOz9QR4df2rKo0IHrxMNxNsUdUxalfMaTFD_PsyQDegdZjrugFj5YRHagpvFwAoHNDPcHL48OPxM8yMeZyEyVJPspaMbb3IQ-5gs2yyZ_jdvmypy-jvbOhH030Go-ydUthBMeBDxpUdfl1Jc-E4wJiIa5SIkbQN8GegyLHZcqS8c2G8EjsW0sd0Bc7oAGotVGjWWJHW9KmLw7ZZRTj5oW2Cmn9H9YyUAMy2xOrniuJnMdQ4zADDAmDRroZiETNUVKqE8h6m6gcEla6g4GQH35TZ6NLZB66PueR4Dm-s9yVQ8sABeYgSwyoUgDkb_p1in5YzAlZrf_gckP0PlhtxdvD3a27qCL4JhHNtG0dRetwp5V98D5nYn7Vu1g9OqshfAH_p2_Lw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Synthesis+and+Structure%E2%80%93Activity+Relationship+Correlations+of+Gnidimacrin+Derivatives+as+Potent+HIV-1+Inhibitors+and+HIV+Latency+Reversing+Agents&rft.jtitle=Journal+of+medicinal+chemistry&rft.au=Liu%2C+Qingbo&rft.au=Cheng%2C+Yung-Yi&rft.au=Li%2C+Wei&rft.au=Huang%2C+Li&rft.date=2019-08-08&rft.issn=0022-2623&rft.eissn=1520-4804&rft.volume=62&rft.issue=15&rft.spage=6958&rft.epage=6971&rft_id=info:doi/10.1021%2Facs.jmedchem.9b00339&rft.externalDBID=n%2Fa&rft.externalDocID=10_1021_acs_jmedchem_9b00339
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-2623&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-2623&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-2623&client=summon